JCT  Vol.3 No.4 , August 2012
Advancements in Suppression of Osteosarcoma Tumorigenicity: A Prospective Look
Abstract: Bone morphogenetic proteins (BMPs) promote differentiation of stem cells into bone cells. Results from our pilot studies indicate these proteins are also capable of inducing the differentiation of stem-like cells that initiate and propagate osteosarcoma, a rare, highly malignant primary bone tumor affecting primarily children and adolescents. Our plans to evaluate the use of BMP as adjuvant therapy to suppress bone tumor while facilitating skeletal reconstruction are reviewed.
Cite this paper: L. Wang, P. Park, F. Marca, K. Than, S. Rahman and C. Lin, "Advancements in Suppression of Osteosarcoma Tumorigenicity: A Prospective Look," Journal of Cancer Therapy, Vol. 3 No. 4, 2012, pp. 327-330. doi: 10.4236/jct.2012.34042.

[1]   P. Picci, “Osteosarcoma (Osteogenic Sarcoma),” Orpha-net Journal of Rare Diseases, Vol. 2, 2007, p. 6. doi:10.1186/1750-1172-2-6

[2]   T. A. Damron, W. G. Ward and A. Stewart, “Osteosarcoma, Chondrosarcoma, and Ewing’s Sarcoma: National Cancer Data Base Report,” Clinical Orthopaedics and Related Research, Vol. 459, 2007, pp. 40-47. doi:10.1097/BLO.0b013e318059b8c9

[3]   D. Bonnet and J. E. Dick, “Human Acute Myeloid Leukemia Is Organized as a Hierarchy that Originates from a Primitive Hematopoietic Cell,” Nature Medicine, Vol. 3, 1997, pp. 730-737. doi:10.1038/nm0797-730

[4]   D. Hanahan and R. A. Weinberg, “The Hallmarks of Cancer,” Cell, Vol. 100, No. 1, 2000, pp. 57-70. doi:10.1016/S0092-8674(00)81683-9

[5]   T. Reya, S. J. Morrison, M. F. Clarke and I. L. Weissman, “Stem Cells, Cancer, and Cancer Stem Cells,” Nature, Vol. 414, No. 6859, 2001, pp. 105-111. doi:10.1038/35102167

[6]   B. Vogelstein and K. W. Kinzler, “Cancer Genes and the Pathways They Control,” Natural Medicine, Vol. 10, No. 8, 2004, pp. 789-799. doi:10.1038/nm1087

[7]   L. Wang, P. Park and C. Y. Lin, “Characterization of Stem Cell Attributes in Human Osteosarcoma Cell Lines,” Cancer Biology & Therapy, Vol. 8, No. 6, 2009, pp. 543- 552. doi:10.4161/cbt.8.6.7695

[8]   L. Wang, P. Park, H. Zhang, F. La Marca and C. Y. Lin, “Prospective Identification of Tumorigenic Osteosarcoma Cancer Stem Cells in OS99-1 Cells Based on High Aldehyde Dehydrogenase Activity,” International Journal of Cancer, Vol. 128, No. 2, 2011, pp. 294-303. doi:10.1002/ijc.25331

[9]   A. M. Cheung, T. S. Wan, J. C. Leung, L.Y. Chan, H. Huang, Y. L. Kwong, R. Liang and A. Y. Leung, “Aldehyde Dehydrogenase Activity in Leukemic Blasts Defines a Subgroup of Acute Myeloid Leukemia with Adverse Prognosis and Superior NOD/SCID Engrafting Potential,” Leukemia, Vol. 21, 2007, pp. 1423-1430. doi:10.1038/sj.leu.2404721

[10]   C. Ginestier, M. H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C. G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M. S. Wicha and G. Dontu, “ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome,” Cell Stem Cell, Vol. 1, No. 5, 2007, pp. 555-567. doi:10.1016/j.stem.2007.08.014

[11]   E. H. Huang, M. J. Hynes, T. Zhang, C. Ginestier, G. Dontu, H. Appelman, J. Z. Fields, M. S. Wicha, B. M. Boman, “Aldehyde Dehydrogenase 1 Is a Marker for Normal and Malignant Human Colonic Stem Cells (SC) and Tracks SC Overpopulation during Colon Tumorigenesis,” The Journal of Cancer Research, Vol. 69, 2009, pp. 3382-3389. doi:10.1158/0008-5472.CAN-08-4418

[12]   M. B. Kastan, E. Schlaffer, J. E. Russo, O. M. Colvin, C. I. Civin and J. Hilton, “Direct Demonstration of Elevated Aldehyde Dehydrogenase in Human Hematopoietic Progenitor Cells,” Blood, Vol. 75, No. 10, 1990, pp. 1947- 1950.

[13]   S. Ma, K. W. Chan, T. K. Lee, K. H. Tang, J. Y. Wo, B. J. Zheng and X. Y. Guan, “Aldehyde Dehydrogenase Discriminates the CD133 Liver Cancer Stem Cell Populations,” Molecular Cancer Research, Vol. 6, 2008, pp. 1146-1153. doi:10.1158/1541-7786.MCR-08-0035

[14]   N. E. Sladek, R. Kollander, L. Sreerama and D. T. Kiang, “Cellular Levels of Aldehyde Dehydrogenases (ALD- H1A1 and ALDH3A1) as Predictors of Therapeutic Responses to Cyclophosphamide-Based Chemotherapy of Breast Cancer: A Retrospective Study. Rational Individualization of Oxazaphosphorine-Based Cancer Chemotherapeutic Regimens,” Cancer Chemotherapy and Pharmacology, Vol. 49, No. 4, 2002, pp. 309-321. doi:10.1007/s00280-001-0412-4

[15]   L. Wang, P. Park, H. Zhang, F. La Marca, A. Claeson, J. Valdivia and C. Y. Lin, “BMP-2 Inhibits the Tumorigenicity of Cancer Stem Cells in Human Osteosarcoma OS99-1 Cell Line,” Cancer Biology Therapy, Vol. 11, No. 5, 2011 pp. 457-463. doi:10.4161/cbt.11.5.14372